Immune Checkpoint Inhibitors (ICI) were shown to improve survival in patients with advanced non-small cell lung cancer. Nevertheless, around 10% of treated patients may have an atypical response with disastrous tumor growth and earlier death. Readily available predictors of such response are still unrevealed and desperately needed.